IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst

• The FDA is reviewing Anktiva plus BCG for papillary-only bladder cancer, with a Jan. 6, 2027 decision date.
• ImmunityBio ended the quarter with $380.9 million in cash and is advancing an AI-powered NK-cell manufacturing platform.
• Retail message volume surged 360% as traders speculated about a global rollout, major news, or possible merger talks.

Shares of ImmunityBio (IBRX) rose 1% in premarket trading on Tuesday despite a newly disclosed reduction in an institutional stake, as retail traders looked past the selling and focused on a potentially imminent global rollout announcement for its flagship immunotherapy, Anktiva.

IBRX stock fell 5% on Monday, ending the session at $7.79. 

Investor Trims IBRX Stake As FDA Catalyst Looms 

Sheets Smith Wealth Management reduced its ImmunityBio position by 39,453 shares, or about 7.2%, according to Quiver Quantitative data. The firm held 512,572 shares worth $4.49 million as of June 30, down from 552,025 shares previously.

The next major regulatory milestone is the U.S. Food and Drug Administration’s (FDA) review of Anktiva plus BCG for papillary-only bladder cancer that no longer responds to standard BCG treatment. The agency accepted ImmunityBio’s application last month and set a Jan. 6, 2027 target decision date.

Anktiva is approved or authorized across 34 countries in five regulatory regions. In the Quilt-3.032 study, 58.2% of patients remained disease-free after 12 months, while more than 80% avoided bladder-removal surgery through three years.

IBRX Investors Eye Q2 Sales Momentum 

Investors are also looking for signs of second-quarter (Q2) commercial momentum after Anktiva helped drive a 168% increase in first-quarter net sales to $44.2 million.

ImmunityBio’s net loss widened to $632.8 million, largely due to accounting adjustments tied to warrants, derivative liabilities and convertible notes. The company ended the quarter with $380.9 million in cash, cash equivalents and marketable securities, up from $242.8 million at the end of 2025. Traders are also tracking founder Patrick Soon-Shiong’s automated natural-killer-cell manufacturing platform. ImmunityBio is developing an AI-powered robotic system designed to automate the handling and production of NK cells for its cell-therapy programs.

Retail Sees Major IBRX News Catalyst

On Stocktwits, retail sentiment for IBRX was ‘bearish’ amid a 360% jump in 24-hour message volumes. Traders focused on the possibility that the company’s recent silence could precede a major announcement.

One user called ImmunityBio a “news driven stock” and said it was “1 news release from a 100% move.” Another said a “global roll-out partner / strategy announcement is imminent,” arguing the quiet period could set up the “mother of all KABOOMSKIS.” Others said it was “time for news” after a lack of major company updates since late May. One trader speculated that Soon-Shiong’s silence could reflect merger discussions, though there is no confirmed evidence of an active transaction.

IBRX stock has surged 177% over the past year. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Read Next: SRXH Stock Falls Premarket Ahead Of Eric Jackson's Fireside Chat — Traders Brace For Buyback Clues And CEO Spotlight